Who Paid My Doc
Sarah Xavier
Child & Adolescent Psychiatry Lincoln, RI Doctor of Osteopathy
NPI 1518942267 CMS profile 205152
652 George Washington Hwy, Suite 400, Lincoln, RI 02865
General payments
$1,316
Research payments
$0
Ownership & investment interest
$0
Through program year 2020, Sarah Xavier of Lincoln, RI is reported in the CMS Open Payments database as having received $1,316 across 71 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 80th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $345 | 19 | |
| 2019 | General | $971 | 52 |
Beside peers
- Sarah Xavier
- Child & Adolescent Psychiatry median
- Middle half of Child & Adolescent Psychiatry
- National median
In program year 2025, general payments to Sarah Xavier were reported at $0. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.
Show as a table
| Year | Sarah Xavier | Child & Adolescent Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $971 | $129 | $42–$419 | $163 |
| 2020 | $345 | $81 | $28–$226 | $114 |
| 2021 | $0 | $115 | $31–$326 | $132 |
| 2022 | $0 | $124 | $40–$382 | $149 |
| 2023 | $0 | $130 | $45–$420 | $160 |
| 2024 | $0 | $141 | $42–$490 | $164 |
| 2025 | $0 | $132 | $41–$474 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
179
Drug cost
$2,689
Branded share of claims
14.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Methylphenidate Er Methylphenidate Hcl | Brand | 13 | $503 | |
| Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine | Brand | 13 | $453 | |
| Olanzapine | Generic | 16 | $413 | |
| Lithium Carbonate | Generic | 15 | $332 | |
| Duloxetine Hcl | Generic | 21 | $302 | |
| Lamotrigine | Generic | 11 | $200 | |
| Sertraline Hcl | Generic | 17 | $196 | |
| Fluoxetine Hcl | Generic | 28 | $116 | |
| Eszopiclone | Generic | 12 | $105 | |
| Clonazepam | Generic | 12 | $58 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.
Records
71 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Child & Adolescent Psychiatry in Rhode Island
Practitioners in the same specialty and state, ranked by reported value.
All Child & Adolescent Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in Rhode Island
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.